Bexion is actively pursuing treatments where there is a significant unmet need and high market potential
BXQ-350 has shown significant clinical promise and selectively kills cancer cells through multiple mechanisms
Bexion’s leadership team has a demonstrated track record of success in bringing life-changing treatments to market
Bexion is undertaking a robust clinical development plan across multiple indications to maximize the value of the BXQ-350 platform
Bexion has generated significant money valuation over time and represents a sound investment choice in the pharma/biotech sector
This document contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are projections of events, revenues, income, future economic, research, development, reformulation, product performance or management’s plans and objectives for future operations. In some cases you can identify forward-looking statements by the use of terminology such as “may”, “should”, “anticipates”, “believes”, “expects”, “intends”, “forecasts”, “plans”, “future”, “strategy”, or words of similar meaning.
Forward-looking statements in this document include statements about the product(s) Bexion Pharmaceuticals, Inc. owns, may own, license, co-promote, co-develop, co-market or otherwise enter into an arrangement with other parties. While these forward-looking statements and any assumptions upon which they are based are made in good faith and reflect current judgment regarding the direction of the business operations of Bexion Pharmaceuticals, Inc., actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested in this Web site. These statements are predictions and involve known and unknown risks, uncertainties and other factors, including the risk that Bexion Pharmaceuticals, Inc. cannot execute its business plan for lack of capital or other resources, distribution, partnering or licensing/acquisition opportunities. Any of these risks could cause Bexion Pharmaceuticals, Inc., or its industry’s, actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by the forward-looking statements on this Web site. Except as required by applicable law, including the securities laws of the United States, Bexion Pharmaceuticals, Inc. does not intend to update any of the forward-looking statements to conform these statements to actual results.